Anti-VEGF Therapeutics Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2030)
Get a Comprehensive Overview of the Anti-VEGF Therapeutics Market Report Prepared by P&S Intelligence, Segmented by Product (Eylea, Lucentis, Beovu), Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-Related Macular Degeneration), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geographic Regions. This Report Provides Insights From 2019 to 2030
Chapter 1. Research Scope
1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
1.4.1. Market size breakdown, by product
1.4.2. Market size breakdown, by disease
1.4.3. Market size breakdown, by distribution channel
1.4.4. Market size breakdown, by region
1.4.5. Market size breakdown, by country
1.5. Market Data Reporting Unit
1.5.1. Value
1.6. Key Stakeholders
Chapter 2. Research Methodology
2.1. Secondary Research
2.1.1. Paid
2.1.2. Unpaid
2.1.3. P&S Intelligence database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
5.1. Market Dynamics
5.1.1. Trends
5.1.2. Drivers
5.1.3. Restraints/challenges
5.1.4. Impact analysis of drivers/restraints
5.2. Impact of COVID-19
5.3. Porter’s Five Forces Analysis
5.3.1. Bargaining power of buyers
5.3.2. Bargaining power of suppliers
5.3.3. Threat of new entrants
5.3.4. Intensity of rivalry
5.3.5. Threat of substitutes
Chapter 6. Global Market
6.1. Overview
6.2. Market Revenue, by Product (2019–2030)
6.3. Market Revenue, by Disease (2019–2030)
6.4. Market Revenue, by Distribution Channel (2019–2030)
6.5. Market Revenue, by Region (2019–2030)
Chapter 7. North America Market
7.1. Overview
7.2. Market Revenue, by Product (2019–2030)
7.3. Market Revenue, by Disease (2019–2030)
7.4. Market Revenue, by Distribution Channel (2019–2030)
7.5. Market Revenue, by Country (2019–2030)
Chapter 8. Europe Market
8.1. Overview
8.2. Market Revenue, by Product (2019–2030)
8.3. Market Revenue, by Disease (2019–2030)
8.4. Market Revenue, by Distribution Channel (2019–2030)
8.5. Market Revenue, by Country (2019–2030)
Chapter 9. APAC Market
9.1. Overview
9.2. Market Revenue, by Product (2019–2030)
9.3. Market Revenue, by Disease (2019–2030)
9.4. Market Revenue, by Distribution Channel (2019–2030)
9.5. Market Revenue, by Country (2019–2030)
Chapter 10. LATAM Market
10.1. Overview
10.2. Market Revenue, by Product (2019–2030)
10.3. Market Revenue, by Disease (2019–2030)
10.4. Market Revenue, by Distribution Channel (2019–2030)
10.5. Market Revenue, by Country (2019–2030)
Chapter 11. MEA Market
11.1. Overview
11.2. Market Revenue, by Product (2019–2030)
11.3. Market Revenue, by Disease (2019–2030)
11.4. Market Revenue, by Distribution Channel (2019–2030)
11.5. Market Revenue, by Country (2019–2030)
Chapter 12. Competitive Landscape
12.1. List of Market Players and their Offerings
12.2. Competitive Benchmarking of Key Players
12.3. Product Benchmarking of Key Players
12.4. Recent Strategic Developments
Chapter 13. Company Profiles
13.1. Biogen Inc.
13.1.1. Business overview
13.1.2. Product and service offerings
13.1.3. Key financial summary
13.2. F. Hoffmann-La Roche Ltd.
13.2.1. Business overview
13.2.2. Product and service offerings
13.2.3. Key financial summary
13.3. Sandoz Group AG
13.3.1. Business overview
13.3.2. Product and service offerings
13.3.3. Key financial summary
13.4. Bausch Health Companies Inc.
13.4.1. Business overview
13.4.2. Product and service offerings
13.4.3. Key financial summary
13.5. Viatris Inc.
13.5.1. Business overview
13.5.2. Product and service offerings
13.5.3. Key financial summary
13.6. Pfizer Inc.
13.6.1. Business overview
13.6.2. Product and service offerings
13.6.3. Key financial summary
13.7. Amgen Inc.
13.7.1. Business overview
13.7.2. Product and service offerings
13.7.3. Key financial summary
13.8. Regeneron Pharmaceuticals Inc.
13.8.1. Business overview
13.8.2. Product and service offerings
13.8.3. Key financial summary
13.9. Bayer AG
13.9.1. Business overview
13.9.2. Product and service offerings
13.9.3. Key financial summary
13.10. Novartis AG
13.10.1. Business overview
13.10.2. Product and service offerings
13.10.3. Key financial summary
13.11. AbbVie Inc.
13.11.1. Business overview
13.11.2. Product and service offerings
13.11.3. Key financial summary
13.12. Xbrane Biopharma AB
13.12.1. Business overview
13.12.2. Product and service offerings
13.12.3. Key financial summary
Chapter 14. Appendix
14.1. Abbreviations
14.2. Sources and References
14.3. Related Reports
